|
|
Article: PowderMed to Conduct U.S. Clinical Trial of DNA-Based Annual Influenza Vaccine.
- Article from:
- Business Wire
- Article date:
- October 2, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Study Will Assess Immunogenicity, Safety and Tolerability of New, Needle-Free Vaccine
OXFORD, U.K. & FREDERICK, Md. -- PowderMed, Ltd., today announced that it will begin testing a DNA-based annual influenza vaccine in a U.S.-based Phase I clinical trial. The study will assess the efficacy of a trivalent influenza vaccine administered to healthy adults using PowderMed's Particle Mediated Epidermal Delivery (PMED[TM]), a needle-free injection device that fires gold particles coated with DNA (encoding influenza virus genes) at supersonic speed into the immune cells of the skin.
Dr. John Treanor, M.D., Professor of Medicine, and of Microbiology and ...